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SUMMARY 
CDC25 phosphatases are important regulators of several steps in the cell 
cycle, including the activation of various cyclin-dependent kinases 
(CDKs). They also play a role in the cellular response to DNA damage. 
Mammalian cells express three forms of CDC25: CDC25A, -B and –C. 
Overexpression of these phosphatases was reported in the development of 
several human malignancies, including melanoma. Therefore, CDC25 
represent promising targets for anticancer drug discovery. Recently, the 
compound NSC 119915 was identified as a new quinonoid CDC25 
inhibitor with potent antiproliferative activity on cancer cells. In order to 
improve the inhibitory potency of this compound, 126 structurally related 
analogs were found by ligand-based chemoinformatic methods. Twenty-
five of these structures were synthesized and analyzed by an in vitro assay 
to evaluate their inhibition properties on CDC25 phosphatases activity. 
Eight of these (5-9, 21, 24, and 25) posssessed high inhibitory activity 
towards CDC25A, -B and –C, and were tested in a cellular context using 
two human melanoma cell lines, A2058 and SAN. Only the compound 7 
(cpd 7) exerted a reduction of proliferative rate of both melanoma cell 
lines, arrested melanoma cells in G2/M, and caused a reduction of the 
protein levels of CDC25A and CDC25C. Furthermore, an intrinsic 
apoptotic pathway was induced, which was mediated by ROS, because it 
was reverted in the presence of antioxidant N-acetyl-cysteine (NAC). 
Finally, cpd 7 provoked a  significant reduction of the Bcl-2/Bax ratio, 
decreased the protein levels of phosphorylated Akt and increased those of 
p53, thus contributing to the regulation of chemosensitivity through the 
control of downstream Akt pathways in melanoma cells. In conclusion, 
our data emphasize that CDC25 could be considered as a possible 
oncotarget in melanoma cells and that cpd 7 is a small CDC25 inhibitor 
that merits to be further evaluated as a chemotherapeutic agent for 
melanoma, likely in combination with other therapeutic compounds 
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RIASSUNTO 
Le fosfatasi CDC25 sono enzimi coinvolti nella regolazione del ciclo 
cellulare che agiscono defosforilando ed attivando specifiche chinasi 
dipendenti da cicline (CDKs). Inoltre, CDC25 svolge un ruolo chiave 
nella modulazione della risposta cellulare al danno al DNA. Sono state 
identificate tre forme di CDC25: CDC25-A, -B e -C, ciascuna 
differentemente implicata nelle diverse fasi del ciclo cellulare. Un’elevata 
espressione di queste fosfatasi è stata riscontrata in numerose neoplasie, 
compreso il melanoma. Pertanto, tali enzimi sono considerati un possibile 
bersaglio molecolare nello sviluppo di nuove strategie terapeutiche 
antitumorali. Recentemente è stato identificato un nuovo inibitore di 
CDC25 a struttura chinonica, il composto NSC 119915. Allo scopo di 
approfondire lo studio sulle proprietà inibitrici di tale molecola, sono stati 
individuati attraverso studi chemoinformatici 126 analoghi di tale “lead 
compound”. Tra questi, 25 composti sono stati sintetizzati e 
successivamente analizzati mediante dosaggi in vitro, per verificare il loro 
potenziale inibitorio sull’attività fosfatasica di CDC25. Solo 8 analoghi 
(5-9, 21, 24 e 25) mostravano un’elevata capacità inibitoria sulle tre 
forme di CDC25, e pertanto il loro potenziale effetto citotossico è stato 
valutato mediante studi biologici in vitro, utilizzando due linee cellulari di 
melanoma umano, A2058 e SAN. Tra gli 8 analoghi selezionati, solo il 
composto 7 induceva una significativa riduzione della capacità 
proliferativa di entrambe le linee di melanoma. In particolare, tale 
analogo provocava l’arresto delle cellule di melanoma in G2/M, causando 
una significativa riduzione dei livelli proteici di CDC25A e CDC25C. 
Inoltre, il composto 7 induceva un processo apoptotico intrinseco caspasi-
dipendente, mediato da un incremento dei livelli intracellulari dei ROS. 
Infine, è stato osservato un effetto di tale composto su alcune vie di 
segnale che regolano processi di apoptosi, proliferazione e sopravvivenza 
cellulare. Infatti, nel corso del trattamento con il composto 7 è stata 
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evidenziata una marcata riduzione del rapporto Bcl-2/Bax, una riduzione 
dei livelli di pAkt ed un incremento di p53. 
Nel complesso, questi dati suggeriscono che CDC25 potrebbe 
rappresentare un “oncotarget” nelle cellule di melanoma e che lo studio 
approfondito dei meccanismi coinvolti nei processi indotti dal composto 7 
potrebbero contribuire a migliorare le prospettive terapeutiche di tale 
neoplasia, attraverso l’utilizzo combinato con altri farmaci 
chemioterapici. 
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INTRODUCTION 
Cell division cycle 25 proteins (CDC25s) are dual-specificity 
phosphatases (DSPs), that dephosphorylate conserved tyrosine and 
threonine residues of the cyclin-dependent kinases (CDKs) complexes; 
this event leads to the activation of these crucial regulators of the 
progression through the cell cycle [1,2]. Furthermore, CDC25s are key 
targets of checkpoint machinery, which is activated in response to DNA 
damage caused by UV light, ionizing irradiation, or chemicals. Therefore, 
the misregulation of these enzymes could be pivotal for causing genomic 
instability. There are three forms of CDC25 phosphatases in mammalian 
cells: CDC25A, -B, and –C [3]. CDC25A mainly controls G1/S 
progression, by dephosphorylating and activating the CDK4-cyclin D [4] 
and CDK6-cyclin D [5], as well as CDK2-Cyclin A and CDK2-Cyclin E 
complexes [6,7]. CDC25B and CDC25C are primarily required for the 
entry into mitosis. CDC25B is responsible for the initial activation of 
CDK1-Cyclin B complex at the centrosome during the G2/M transition, 
which is then followed by a complete activation of CDK1-cyclin B 
complexes by CDC25C in the nucleus at the onset of mitosis [8,9]. 
However, all three CDC25 forms are involved in the G1/S and G2/M 
transitions and in mitosis (Figure 1). CDC25 phosphatase activity is 
tightly regulated at transcriptional level and by multiple post-translational 
mechanisms such as inhibitory and activated phosphorylations, sub-
cellular relocalization and proteasome-mediated degradation [10], and by 
p53-dependent transcriptional repression [11,12]. The expression of 
CDC25A, CDC25B or both has been shown to be upregulated in a wide 
variety of human tumors, including melanoma [13]. With regard to 
CDC25C, only a few studies showed an overexpression of this form in 
tumours [14,15]. 
CDC25 overexpression can probably occur at different steps during 
tumorigenic pathway and contributes to the progression of the disease 
through a deregulation of the cell division cycle, cooperating with other 
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oncogenes involved in signalling pathway. Therefore, CDC25 
phosphatases can represent ideal targets for the development of novel 
anticancer therapies [8]. 
 
 
 
Figure 1. An overview of the regulatory function of CDC25s in cell cycle progression. 
At G0-phase, cells that had been quiescent, re-enter the cell cycle after activation of 
CDK3/cyclin C. Dephosphorylation of CDK4/cyclin D, CDK6/cyclin D and CDK2 both 
in complex with cyclin E and cyclin A by CDC25s leads to the transition into the DNA-
replication phase. At late S-phase, CDC25B activates CDK1/cyclin A. Finally, 
dephosphorylation of CDK1/cyclin B triggers mitotic entry, and in this important step all 
three CDC25 isoforms are involved. At the end of mitosis, both CDK1/cyclin B and the 
CDC25s are degraded and the cycle can start all over again.  
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A number of compounds, belonging to various chemical classes 
(phosphate bioisosteres, electrophilic entities, and quinone-based 
structures) have shown to possess an in vitro inhibitory power on CDC25 
phosphatase activity. It is thought that there are three possible 
mechanisms through which these molecules may inhibit CDC25: 
reversible inhibition through binding to the active site of CDC25 [16,17], 
irreversible inhibition through a direct binding of the inhibitor to CDC25 
[18,19], or oxidation of a critical cysteine residue (CX5R) in the catalytic 
domain  of these enzymes by reactive oxygen species (ROS) generated in 
cultured cells treated with quinone derivatives [20,21]. 
Many of the most potent CDC25 inhibitors are quinone-containing 
compounds, which inhibit in vitro all three forms of CDC25 in an 
unselective manner. Among these, NSC 95397 [16], NSC 663284 [18], 
BN 82685 [22] and IRC-083864 [23] are representative potent inhibitors 
(Figure 2). Recently, a new quinonoid CDC25 inhibitor, NSC 119915, 
has been discovered; this compound displayed irreversible inhibition, 
generated an increase of the intracellular ROS level, arrested cells in the 
G0/G1 and G2/M phases of the cell cycle, and significantly suppressed 
the growth of human MCF-7 breast, PC-3 prostate, and K562 leukemia 
cancer cell lines [24]. 
 
 
Figure 2: Known quinone-containing CDC25 Inhibitors.  
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It is known that malignant melanoma is an aggressive and deadly tumour 
with a high tendency to relapse and high metastasis rate. The 
development and progression of melanoma is often associated with 
alteration of some components of key signalling pathway that regulate 
proliferation, survival, growth factor receptor activation, differentiation, 
cell adhesion and migration. Hence, the discovery of new molecules 
acting through the modulation and inhibition of key pathways involved in 
cell proliferation and survival will be very helpful in the development of 
new therapeutic strategies against melanoma. 
In this study, we characterized the inhibitory power of twenty-five 
analogs of NSC 119915. Among them, eight compounds, sharing the 
same 6-xanthone chemical motif (5-9, 21, 24, and 25), exerted an in vitro 
inhibitory activity towards all three CDC25 forms, comparable with that 
shown by NSC 119915. We also investigated the cytotoxic effect of these 
molecules in a cellular context, using two melanoma cell lines, A2058 
and SAN. The resultes indicated that only cpd 7 exerted a significant 
effect on the inhibition of cell proliferation, as revealed by the 
cytotoxicity tests. Furthermore, cpd 7 altered the cell cycle progression, 
modulated the CDC25 protein levels and caused the cell death, by 
inducing an apoptotic program, as evaluated through different markers. In 
addition, 7 induced an alteration of the cellular redox state and provoked a 
mitochondrial dysfunction, likely associated to the modulation of the 
pAkt and p53 protein levels. 
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2. MATERIALS AND METHODS 
2.1 Materials and Reagents 
Compounds, purchased from commercial vendors or kindly provided 
from the NCI/DTP, were dissolved in dimethyl sulfoxide (DMSO), and 
stock solutions at 10 mM concentration were prepared. Recombinant 
forms of the catalytic domains of CDC25A, -B and -C were obtained 
through the vectors pET28a-CDC25A-cd, pET28a-CDC25B-cd and 
pET28a-CDC25C-cd, kindly provided by H. Bhattacharjee (Florida 
International University, Herbert Wertheim College of Medicine, Miami, 
Florida), using the procedure already described [24]. The synthetic 
substrate for CDC25 phosphatase activity, 3-O-metylfluorescein 
phosphate (OMFP), was purchased from Sigma-Aldrich. Dulbecco's 
modified Eagle's medium (DMEM), Roswell Park Memorial Institute 
(RPMI) 1640 medium, fetal bovine serum (FBS), L-glutamine, penicillin 
G, streptomycin, and trypsin were purchased from Lonza (Milano, Italy). 
Propidium iodide (PI), dichlorofluorescein diacetate (DCFH-DA), 
Rhodamine 123 (R123), apocynin and N-acetyl-L-cysteine (NAC) were 
purchased from Sigma-Aldrich. A protease inhibitor cocktail was 
obtained from Roche Diagnostics S.p.A. (Monza, Italy). Caspase-3 and 
caspase-9 fluorimetric assay kits were purchased from BioVision 
(Milpitas, CAβ, USA). The pan-caspase inhibitor Z-VAD-FMK was 
purchased from Selleckchem (USA). Rabbit monoclonal antibody against 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was obtained from 
Cell Signaling (Boston, MA, USA); mouse monoclonal antibody against 
CDC25A, CDC25C or Bcl-2, rabbit polyclonal antibody against 
CDC25B, pAkt or Bax, and each secondary antibody conjugated to 
horseradish peroxidase were obtained from Santa Cruz Biotechnology 
(Heidelberg, Germany). All other chemicals were of analytical grade and 
were purchased from Sigma-Aldrich. 
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2.2 Database and chemoinformatic methods 
Chemoinformatic methods for the selection of 126 structurally related 
analods of NSC 119915 were carried out in collaboration with the 
Department of Pharmacy, University of Naples Federico II. The NCI 
Open Database (http://dtp.cancer.gov/) was obtained from ZINC [25,26]. 
The compound database was processed with FILTER version 2.0.2 
(OpenEye Scientific Software Inc., Santa Fe, USA, 
http://www.eyesopen.com/) to select a subset of lead-like compounds. 
The default parameters in the lead-like filter were used without further 
modifications. The resulting database was referred in this thesis as the 
NCI lead-like set. 
 
2.3 In vitro assays of CDC25 phosphatase activity 
The enzymatic activity of the catalytic domains of CDC25A, -B and -C 
were determined through a fluorimetric method, which monitored the 
dephosphorylation of the synthetic substrate OMFP, essentially as 
previously described [24]. In particular, the effect of the various inhibitors 
was first evaluated on the phosphatase activity of CDC25B in steady-state 
enzyme kinetic studies. To this aim, the activity of purified recombinant 
CDC25B was measured at 30°C in the presence of different 
concentrations of the various inhibitors, using a computer-assisted Cary 
Eclipse spectrofluorimeter (Varian) equipped with an electronic 
temperature controller. Excitation and emission wavelengths were set at 
485 and 530 nm, respectively; both excitation and emission slits were set 
at 10 nm. The reaction mixture contained 10 nM CDC25B and different 
concentrations of the various inhibitors in 500 µL final volume of 20 mM 
Tris-HCl, pH 7.8, 1 mM dithiothreitol (DTT). DMSO was used as vehicle 
control. The reaction started with the addition of 25 µM OMFP, and the 
formation of the fluorescent product o-methylfluorescein was monitored 
continuously. The rate of OMFP hydrolysis was expressed as arbitrary 
units per min (a.u./min). The comparison of the rates determined in the 
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absence and in the presence of the various inhibitors allowed the 
calculation of the residual phosphatase activity, expressed as a 
percentage. 
To measure the inhibition constant (Ki) of the recombinant forms of 
CDC25A, -B and -C towards the various inhibitors, the affinity of the 
different forms of CDC25 towards OMFP was measured either in the 
absence or in the presence of fixed concentrations of the various 
inhibitors. The reaction mixture contained 20 nM CDC25A, or 10 nM 
CDC25B, or 40 nM CDC25C, and different concentrations of the various 
inhibitors in 500 µL final volume of 20 mM Tris-HCl , pH 7.8, 1 mM 
DTT. DMSO was used as vehicle control. The reaction started with the 
addition of 1–25 µM OMFP, and the rate of OMFP hydrolysis was 
measured as indicated before. The corresponding Lineweaver-Burk plots 
allowed the calculation of the KM for OMFP and of the maximal rate 
(Vmax) of OMFP hydrolysis. In the presence of the various inhibitors the 
KM for OMFP remained essentially unchanged, whereas the Vmax 
decreased, thus indicating that the selected compounds were 
noncompetitive inhibitors of CDC25. The Ki values were obtained from 
the decrease of Vmax in the presence of the inhibitor, according to the 
equation Vmaxʹ = Vmax/{1+([I]/Ki)}, where Vmaxʹ represents the Vmax 
measured in the presence of the concentration [I] of the inhibitor. The Ki 
values were obtained from at least three independent experiments and 
reported as mean ± S.E. 
 
2.4 Cell culture 
The human melanoma cell line A2058, kindly provided by CEINGE 
(Naples, Italy), and SAN cells [27] were derived from lymph nodal 
metastases and grown in DMEM and RPMI 1640, respectively, 
supplemented with 10% FBS, 2 mM L-glutamine, 100 IU/mL penicillin 
G, and 100 µg/mL streptomycin in humidified incubator at 37°C under 
5% CO2 atmosphere. All cells were split and seeded every three days and 
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used during the exponential phase of growth. Cell treatments were always 
carried after 24 h from plating. 
 
2.5 3-(4,5-Dimethylthiazole-2-yl)-2,5-biphenyltetrazolium bromide 
(MTT) assay 
The MTT assay was used to detect cell proliferation essentially as 
previously described [28]. Briefly, A2058 and SAN cells were plated in 
96-well microtiter plates (100 µL/well) at 4000 and 6000 cells/well, 
respectively. After 24-h seeding, cells were treated with the selected 
compounds added at 25, 50 or 100 µM concentration, or with 0.5% (v/v) 
DMSO as a vehicle control. After 24-h, 48-h or 72-h treatment, and upon 
the addition of 10 µL of MTT solution in the dark, the plate was 
incubated for 3 h at 37°C under CO2 atmosphere. After medium 
aspiration and solubilization of formazan crystals, absorbance was 
measured at 570 nm, using an ELISA plate reader (Bio-Rad, Milano, 
Italy). 
 
2.6 Cell cycle analysis and evaluation of apoptosis 
Cells were seeded into 6-well plates at 3 × 105 cells/well for 24 h at 37°C; 
after the addition of 100 µM cpd 7 or 0.5% DMSO as a vehicle control, 
the incubation of treated cells continued for 16 or 24 h. After each 
treatment, cells were harvested with trypsin, centrifuged and the pellet 
was resuspended in phosphate-buffered saline (PBS). For cell cycle 
analysis, cells were fixed with 70% (v/v) cold ethanol and stored at –20°C 
for 1 h. Then, cells were washed with cold PBS, centrifuged and the 
pellets were resuspended in 200 µL of a non-lysis solution containing 50 
µg/mL PI. For the evaluation of apoptosis, cells were not fixed in ethanol 
and directly resuspended in 200 µL of a hypotonic lysis solution 
containing 50 µg/mL PI. After incubation at 4°C for 30 min, cells were 
analyzed with a FACScan flow cytometer (Becton Dickinson) for 
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evaluating the distribution in cell cycle phases or the presence of nuclei 
with a DNA content lower than the diploid. 
 
2.7 Measurements of caspase-3 and caspase-9 activity 
To estimate caspase-3 and caspase-9 activity during the treatment with 
cpd 7, the respective enzymatic activities were measured by using 
caspase-3 and caspase-9 fluorimetric assay kits, according to the 
manufacturer’s protocol, essentially as previously described [29]. Briefly, 
cells were seeded into 75 cm2  plates (2 × 106 cells/plate) for 24 h at 37°C 
and then treated with 100 µM 7 or 0.5% DMSO. At the end of each 
incubation, cells were collected, washed with PBS, and finally lysed at 
4°C in the cell lysis buffer. Cell lysates were incubated with 50 µM 
DEVD-AFC or LEHD-AFC substrates at 37°C for 2 h, to detect caspase-
3 or caspase-9 activity, respectively, using a Cary Eclipse fluorescence 
spectrophotometer (Varian). Excitation and emission wavelengths were 
set at 400 nm and 505 nm, respectively; both excitation and emission slits 
were set at 10 nm. 
 
2.8 Measurement of intracellular ROS content 
The intracellular ROS level was monitored using the oxidation-sensitive 
fluorescence probe DCFH-DA. Cells were seeded into 6-well-plates (3 × 
105 cells/plate) for 24 h at 37°C and then treated at various times with 100 
µM cpd 7 or 0.5 % DMSO. DCFH-DA was added in the dark at 10 µM 
final concentration 30-min before the end of each incubation; then, cells 
were collected, washed in PBS, and finally resuspended in 500 µL PBS 
for fluorimetric analysis. Measurements were realized in the above-
mentioned fluorescence spectrophotometer; excitation and emission 
wavelengths were set at 485 nm and 530 nm, respectively; both excitation 
and emission slits were set at 10 nm. The effect of 7 on ROS production 
was also estimated after pretreatment of cells with 10 mM NAC for 1 h. 
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2.9 Evaluation of mitochondrial membrane potential 
Mitochondrial membrane potential was evaluated by measuring the 
incorporation of the fluorescent probe R123, essentially as previously 
described [30]. Briefly, cells were seeded into 6-well-plates (3 × 105 
cells/well) for 24 h at 37°C, and then incubated at 37°C for 1 h in the 
presence of 5 µM R123, washed twice with PBS, and placed in medium 
containing 100 µM cpd 7 or 0.5% DMSO. After various times from 
treatment, cells were harvested, washed and centrifuged for 10 min at 
4°C. The cellular pellet was resuspended in 500 µL PBS. The 
fluorescence of cell-associated R123 was detected in the above-
mentioned fluorescence spectrophotometer, using excitation and emission 
wavelengths of 490 and 520 nm, respectively; both excitation and 
emission slits were set at 10 nm. 
 
2.10 Western blotting 
A2058 cells were seeded into 6-well-plates (3 × 105 cells/plate) for 24 h at 
37°C and then treated at different times with 100 µM cpd 7 or 0.5% 
DMSO. After treatment, cells were harvested, washed with PBS and then 
lysed in ice-cold modified radio immunoprecipitation assay (RIPA) buffer 
(50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.25% 
sodium deoxycholate, 1 mM Na3VO4 and 1 mM NaF), supplemented with 
protease inhibitors and incubated for 30 min on ice. The supernatant 
obtained after centrifugation at 12,000 rpm for 30 min at 4°C constituted 
the total protein extract. The protein concentration was determined by the 
method of Bradford, using bovine serum albumin as standard [31]. Equal 
amounts of total protein extracts were used for Western blotting analysis. 
Briefly, protein samples were dissolved in SDS-reducing loading buffer, 
run on 12% SDS/PAGE and then transferred to Immobilon P membrane 
(Millipore). The filter was incubated with the specific primary antibody at 
4°C overnight and then with the secondary antibody at room temperature 
for 1 h. Membranes were then analysed with an enhanced 
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chemiluminescence reaction, using Super Signal West Pico kit (Pierce) 
according to manufacturer’s instructions; signals were visualized by 
autoradiography. 
 
2.11 Statistical analysis 
Data are reported as average and standard error. The statistical 
significance of differences among groups was evaluated using ANOVA, 
with the Bonferroni correction as post hoc test or the Student t test where 
appropriate. The significance was accepted at the level of p < 0.05. 
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3. RESULTS 
3.1 Compound selection using chemoinformatics 
The present work was aimed at the identification of novel structural 
analogs with increased CDC25 inhibition power compared to the lead 
compound NSC 119915. To this aim, a database of compound structures 
from ZINC drug-like library and NCI lead-like set was used in 
collaboration with the Department of Pharmacy, University of Naples 
Federico II. After combination of the results obtained with these 
databases, and elimination of duplicate structures, a total of 126 unique 
compounds were identified, that were predicted to be similar in some way 
to the lead compound NSC 119915 by one or more methods (Figure 3). 
 
 
 
 
Figure 3: Flow chart of the multiple ligand-based chemoinformatic strategy 
implemented in this work.  
To avoid an extensive and time-consuming screening of such a great 
number of compounds by in vitro assays, top-ranked 25 compounds were 
selected, and purchased or requested from the NCI Developmental 
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Therapeutics Program (DTP) (Table 1). 
Table 1: Compounds identified by multiple ligand-based 
chemoinformatic protocol  
 
 
3.2 Effect of the close analogs of NSC 119915 on the phosphatase 
activity of purified recombinant forms of CDC25 
As a primary approach to the identification of novel structures with 
increased inhibition potency towards CDC25, we have evaluated the 
inhibition properties of the close analogs of NSC 119915 through a 
fluorimetric assay, that measured the residual phosphatase activity of the 
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recombinant form of CDC25B in the presence of the various compounds. 
Among the twenty-five molecules selected from the multiple ligand-based 
chemoinformatic approach, eight compounds (2, 10, 12-14, and 16-18) 
were excluded from the analysis, because endowed with a strong 
fluorescent signal, which interfered with the emission wavelength of the 
synthetic substrate OMFP used in the fluorimetric assay. The inhibition of 
the phosphatase activity of CDC25B by the remaining seventeen analogs 
was evaluated in the presence of two different concentrations of these 
compounds (Table 2). 
 
Table2: Residual phosphatase activity of CDC25B in the presence of 
compound NSC 119915 or its 6-xanthone analogs 
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The data indicated that nine compounds (1, 3, 4, 11, 15, 19, 20, 22, and 
23) caused a measurable inhibition of the phosphatase activity, only when 
added at the highest concentration. Therefore, most of these compounds 
were excluded from the following analysis. In contrast, eight analogs (5-
9, 21, 24, and 25), all of them containing a 6-xanthone chemical motif, 
exerted a concentration-dependent inhibition of the CDC25B phosphatase 
activity, with a percentage of inhibition comparable to that exhibited by 
the lead compound NSC 119915. Therefore, these eight analogs were 
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chosen for the following studies and one compound from the less active 
group, i.e. cpd 3, was included in the subsequent analysis. 
To better investigate the inhibition properties of the effective analogs, 
their Ki values were determined, using the three different CDC25 
proteins. Figure 4 shows the kinetic evaluation of the inhibitory effect 
exerted by one of these compounds, i.e. cpd 7, on the three CDC25 forms. 
Indeed, the behaviour of this compound was similar to that observed with 
the other 6-xanthone derivatives; therefore, the behaviour of 7 was 
considered as representative of the inhibition mechanism exerted by all 
these compounds. 
 
Figure 4: Effect of compound 7 on the Lineweaver-Burk plots of the A. CDC25A B. 
CDC25B and C. CDC25C phosphatase activity. The phosphatase activity was 
measured through the rate of OMFP hydrolysis as described in the Materials and 
Methods. The activity was determined either in the absence (empty circles in A., B. and 
C.) or in the presence of the following concentrations of compound 7: 0.5 µM (filled 
triangles in A.), 0.25 µM or 0.5 µM (filled triangles or filled circles, respectively, in B.), 
1 µM (filled triangles in C.).  
 
The Ki of the tested compounds towards the three different CDC25 forms 
are reported in Table 3; their low values confirmed that these compounds 
possessed a strong inhibition towards CDC25A, -B or -C. Indeed, the 
measured Ki values obtained for the 6-xanthone derivatives were similar 
to that determined for NSC 119915 and all comprised in relatively small 
intervals; in particular, the Ki towards CDC25A ranged between 0.01 and 
Results 
17 
 
0.80 µM, and the corresponding intervals for CDC25B and CDC25C 
were 0.12 – 2.4 µM and 0.30 – 4.4 µM, respectively. Among the three 
forms, CDC25A showed a slightly higher sensitivity towards the 
inhibitors, whereas CDC25C had a moderately lower responsiveness. 
Concerning the mechanism of inhibition exerted by the 6-xanthone 
analogs, the kinetic measurements showed that the tested compounds had 
a behavior similar to that already reported for NSC 119915 [24]. In 
particular, in the presence of the inhibitors, the KM value for the substrate 
OMFP was not essentially modified, whereas the Vmax of phosphatase 
activity was significantly reduced. Therefore, the tested analogs of NSC 
119915 were non-competitive inhibitors of CDC25 and probably acted in 
an irreversible manner. 
 
Table 3: Ki values of compound NSC 119915 or its 6-xanthone 
analogs towards CDC25A, -B, -C phosphatases 
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3.3 Evaluation of CDC25 inhibitors on cell growth rate of A2058 and 
SAN melanoma cells 
The potent antiproliferative action of NSC 119915 on some cancer cell 
lines deriving from breast or prostate carcinoma, as well as from acute 
myeloid leukemia, was recently described [24]. In the present work the 
biological effects of these compounds were evaluated, using two 
melanoma cell lines, i.e. A2058 and SAN, as a cellular system. The 
cytotoxic effects of the lead compound and its analogs on the growth rate 
of the melanoma cell lines was investigated. In particular, the effect of the 
inhibitors was monitored after different times of treatment with 25, 50 or 
100 µM NSC 119915 or its analogs 3, 5-9, 21, and 24-25. Figure 5 shows 
the cell growth rate of A2058 and SAN cells after 48-h treatment in the 
presence of 100 µM of the various compounds. This concentration was 
considered the minimum dose of inhibitor that caused an evident 
cytotoxic activity in melanoma cells. As shown in Figure 5A, only the 
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analog 7, among the nine compounds, caused a significant reduction of 
the cell growth rate of A2058, whereas the other 6-xanthone derivatives, 
as well as NSC 119915, were quite ineffective or caused a not significant 
reduction of cell growth rate. A similar behavior was observed after 72-h 
incubation, because only cpd 7 provoked the significant reduction of cell 
growth rate (data not shown). Figure 5B reports the effects of the 
inhibitors in SAN cells. Three compounds, i.e. 6, 7 and 24, caused a 
significant reduction of cell growth rate after 48-h treatment; however, 
when the treatment was prolonged up to 72 h, also compound NSC 
119915 exerted a significant reduction of cell growth rate (not shown). 
Therefore, cpd 7, showing its cytotoxicity in both cell lines starting from 
48-h treatment, was considered as representative of the effect of this 
group of molecules in melanoma cells and was used for further 
experiments. 
 
Figure 5: Effect of NSC 119915 and its close analogs on cell growth rate of 
melanoma cells. A. A2058 and B. SAN cells were incubated for 48 h with 0.5% DMSO 
as a vehicle control or 100 µM of each of the indicated compounds. The cell growth rate 
is reported as arbitrary units (a.u.). Data from four independent experiments are reported 
as the means ± SE. *p < 0.05 and **p < 0.01 compared to control cells.  
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3.4 Effect of compound 7 on cell cycle progression and apoptosis 
CDC25 phosphatases are crucial regulators of cell cycle and for this 
reason, the effect of 7 on cell cycle progression was studied in detail. To 
this aim, asynchronously growing A2058 cells were treated at different 
times with 100 µM cpd 7, and then cell cycle analysis was 
cytofluorimetrically monitored after PI incorporation. Figure 6 shows the 
time-dependent distribution of the cell cycle in its different phases. In 
particular, after 16-h incubation with vehicle alone, cells were mainly and 
almost equally distributed in G0/G1 and G2/M phases (the ratio between 
them being 0.96), with an almost undetectable representation in the S-
phase; conversely, after 16-h treatment with cpd 7, a significant decrease 
of cells in G0/G1 phase was evident, accompanied by a remarkable 
improvement of the G2/M cell arrest (the ratio between G0/G1 and G2/M 
decreased to 0.38), as shown in Figure 6A. If the incubation with the cpd 
7 was prolonged up to 24 h, the distribution of the different phases of cell 
cycle was essentially identical to that obtained at 16 h (Figure 6B). 
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Figure 6: Effect of compound 7 on the distribution of cell cycle phases of A2058 
cells. The determination of cells in the different phases was evaluated after A. 16 h or B. 
24 h from treatment with 0.5% DMSO or 100 µM compound 7, as described in the 
Materials and Methods. Histograms, which show the cell percentage among the various 
phases, were obtained from triplicate experiments and reported as the means ± SE. *p < 
0.05 and **p < 0.01 compared to control cells. Vehicle alone, open bars; compound 7, 
black bars.  
Furthermore, a similar general picture emerged from the effect of cpd 7 
on cell cycle progression of SAN cells (Figure 7). 
 
 
 
Figure 7: Effect of compound 7 on the distribution of cell cycle phases of SAN cells. 
The determination of cells in the different phases was evaluated after (A) 16 h or (B) 24 
h from treatment with 0.5 % DMSO or 100 µM compound 7, as described in the 
Materials and Methods. Histograms, which show the cell percentage among the various 
phases, were obtained from triplicate experiments and reported as the means ± SE.  ** p 
< 0.01,  *** p < 0.001 and **** p < 0.001 compared to control cells. Vehicle alone, 
open bars; compound 7, black bars. 
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Considering that CDC25 phosphatases are key cell cycle regulators, and 
that the previous in vitro data indicated that cpd 7 was a potent inhibitor 
of this important enzyme, we have investigated the cytotoxic effect of this 
compound at the molecular level. In particular, we have evaluated if the 
treatment of A2058 cells with 7 affected also the protein levels of the 
three CDC25 forms. The Western blotting analysis reported in Figure 8 
shows that compound 7 induced a reduction of both CDC25A and 
CDC25C protein levels. In particular, an early decrease of the CDC25A 
was observed up to 4 h compared to untreated cells. A progressive and 
significant reduction of the CDC25C protein levels was observed starting 
from 4 h and continuing at least up to 16 h. On the other hand, the protein 
levels of CDC25B were not affected by treatment of A2058 cells with 7. 
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Figure 8: Effect of compound 7 on CDC25A, B and C protein levels. Total protein 
extracts from A2058 cells, incubated with 0.5% DMSO (open bars) or 100 µM 
compound 7 (black bars) for 2, 4, 8 or 16 h, were analyzed by Western blotting. GAPDH 
was used as loading control. The doublets observed in the immunoblots detecting 
CDC25A or CDC25C were due to the common presence of multiple isoforms of these 
proteins. Densitometric analysis is shown in the lower panel. Data from triplicate 
experiments were reported as the means ± SE. *p < 0.05, **p < 0.01, ***p < 0.001, 
compared to control cells. Other details as described in the Materials and Methods.  
 
An earlier reduction of CDC25C protein levels was observed even in 
SAN cells treated with cpd 7 (Figure 9). Therefore, the arrest of both 
melanoma cells in G2/M phase could be also related to a modulation of 
the CDC25 protein levels induced by 7. 
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Figure 9: Effect of compound 7 on CDC25C protein levels. Total protein extracts 
from SAN cells, incubated with 0.5 % DMSO (open bars) or 100 µM compound 7 (black 
bars) for 1, 2, or 4 h, were analyzed by Western blotting. GAPDH was used as loading 
control. Densitometric analysis is shown in the lower panel. Data from triplicate 
experiments were reported as the means ± SE. * p < 0.05, ** p < 0.01, compared to 
control cells. Other details as described in the Materials and Methods. 
 
 
The effect of 7 on cell growth and cycle progression could suggest the 
beginning of a cell death program. This hypothesis was investigated 
through various methodological approaches. It is known that the number 
of nuclei with a sub-diploid content is a typical hallmark of apoptosis. To 
this aim, PI incorporation was carried out by a flow cytometric analysis 
after treatment of melanoma cells with 100 µM cpd 7. A time-dependent 
increase of apoptosis was evident in A2058 cells (Figure 10A). In 
particular, the effect of 7 on the cell death program became significant 
already at 48 h, and after 72-h incubation, a 18-fold increase of apoptosis 
was reached. Interestingly, after 72-h incubation of SAN cells, a similar 
16-fold increase of apoptotic cells was observed upon treatment with 100 
µM cpd 7 (Figure 10B). Furtheremore, to better investigate the capacity 
of 7 to induce apoptosis, the enzymatic activity of caspase-3, the final 
effector of the apoptotic program, was monitored. Hence, caspase-3 
activity was spectrofluorimetrically measured in both melanoma cells 
after a 24-h treatment with 100 µM cpd 7. As clearly shown for A2058 
(Figure 10C) and SAN cells (Figure 10D), this inhibitor provoked a 
significant increase of the enzymatic activity of caspase-3. 
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Figure 10: Effect of compound 7 on the apoptosis of A2058 and SAN cells. The 
apoptotic process was evaluated in A2058 (panels A. and C.) and SAN (panels B. and 
D.) cells either through the determination of the number of cells with a subdiploid DNA 
content (A. and B.) or by measuring the caspase-3 enzymatic activity (C. and D.). Cells 
were treated with 0.5% DMSO (open bars) or 100 µM compound 7 (black bars) for the 
indicated incubation times. Apoptosis was expressed as a percentage, whereas caspase-3 
activity was reported as arbitrary units (a.u.). Data from triplicate experiments were 
reported as the means ± SE. *p < 0.05, **p < 0.01, ****p < 0.0001, compared to control 
cells. Other details as described in the Materials and Methods.  
 
To confirm that the pro-apoptotic effect of 7 was caspase-mediated, the 
48-h treatment of A2058 and SAN cells with cpd 7 was also carried out in 
the presence of an irreversible pan-caspase inhibitor, such as Z-VAD-
FMK. The data reported in Figure 11 indicate that the level of apoptosis 
caused by 7 was significantly decreased in the presence of the pan-
caspase inhibitor in either A2058 or SAN cells, thus demonstrating that 
the pro-apoptotic effect of 7 was mainly caspase-dependent. These overall 
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data support the hypothesis that cell cycle arrest in G2/M phase caused by 
7 could evolve in an apoptotic process. 
 
 
Figure 11: Effect of Z-VAD-FMK, a pan-caspase inhibitor, on the apoptotic process 
induced in melanoma cells by compound 7. A2058 (panel A.) and SAN (panel B.) 
cells were treated with 0.5% DMSO or 100 µM compound 7 and incubated in the 
absence or in the presence of 100 µM Z-VAD-FMK; the apoptosis was evaluated after a 
48-h incubation through the determination of the number of cells with a subdiploid DNA 
content. Data from triplicate experiments were reported as the means ± SE. **p < 0.01, 
***p < 0.001 and ****p < 0.0001 compared to respective control cells. Other details as 
described in Materials and Methods.  
 
3.5 Effect of compound 7 on ROS generation and mitochondrial 
membrane potential 
It is known that the high redox reactivity of quinonoid molecules, like cpd 
7, could greatly perturbate the intracellular redox state. To this aim, the 
intracellular ROS level was monitored in melanoma cells after their 
treatment with 100 µM cpd 7. Indeed, a time-dependent increase of the 
ROS level was observed upon treatment of A2058 cells with the inhibitor 
7, that became significant already after 4-h (Figure 12A). Futheremore, 
we have also evaluated the possible reversion of the oxidant effect of 7 in 
the presence of a broad-range antioxidant molecule, such as NAC, or the 
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specific inhibitor of NADPH oxidase apocynin. To this aim, A2058 cells 
were pre-incubated for 1 h with 10 mM NAC or for 45 min with 0.5 mM 
apocynin, and then treated for 4 h with the inhibitor 7. As clearly shown 
in Figure 12B, only NAC prevented the increase of ROS level, wheras 
apocynin was unable to revert this increase. We have also evaluated if the 
increase of ROS level caused by cpd 7 could mediate the observed 
apoptotic process induced by this inhibitor. Indeed, the increase of the 
number of apoptotic cells observed upon 48-h treatment with 100 µM 
compound 7 was in a great part reverted by the cellular pre-treatment with 
NAC (Figure 12C). 
 
 
Figure 12: ROS production and their involvement in the apoptotic process of 
A2058 cells, as induced by treatment with compound 7. A. Time-dependent 
measurement of ROS production. Cells were incubated with 0.5% DMSO (open bars) or 
100 µM compound 7 (black bars) and then the intracellular ROS level was measured. B. 
Effect of antioxidant molecules on ROS production. The ROS level was also measured 
in cells untreated or pretreated with NAC or apocynin after a 4-h incubation with DMSO 
or 7. C. Effect of NAC on apoptosis. The PI incorporation was evaluated in cells 
untreated or pretreated with NAC after a 48-h incubation with DMSO or 7. ROS 
production was expressed as a.u., and apoptosis as a percentage. Data from triplicate 
experiments were reported as the means ± SE. *p < 0.05 and **p < 0.01 compared to 
control cells. Other details as described in the Materials and Methods.  
As clearly shown in Figure 13, the same overall picture was observed also 
with SAN cells. Therefore, all these results suggest that 7 altered the 
intracellular redox state of melanoma cells, thus mediating the observed 
Results 
28 
 
cytotoxicity. 
 
Figure 13: ROS production and their involvement in the apoptotic process of SAN 
cells, as induced by treatment with compound 7. (A) Time-dependent measurement of 
ROS production. Cells were incubated with 0.5 % DMSO (open bars) or 100 µM 
compound 7 (black bars) and then the intracellular ROS level was measured. (B) Effect 
of antioxidant molecules on ROS production. The ROS level was also measured in cells 
untreated or pretreated with NAC or apocynin after a 4-h incubation with DMSO or 7. 
(C) Effect of NAC on apoptosis. The PI incorporation was evaluated in cells untreated or 
pretreated with NAC after a 48-h incubation with DMSO or 7. ROS production was 
expressed as a.u., and apoptosis as a percentage. Data from triplicate experiments were 
reported as the means ± SE. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001  
compared to relative control cells. Other details as described in the Materials and 
Methods. 
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Mitochondria represent the primary source of ROS, as well the target of 
ROS action; therefore, we have investigated if the treatment of melanoma 
cells with cpd 7 could affect the mitochondrial functionality. To this aim, 
the variation of the mitochondrial membrane potential was 
fluorimetrically monitored after a time-dependent incubation of A2058 
cells with 7. This molecule provoked a reduction of the fluorescent signal, 
corresponding to a decrease  of the mitochondrial membrane potential, 
that was already evident after 24 h and then continued at least up to 72 h 
(Figure 14A). Proteins belonging to the B-cell lymphoma-2 (Bcl-2) 
family are involved in the modulation of the mitochondrial functionality 
[32,33]. Hence, we have assessed the levels of the anti-apoptotic protein 
Bcl-2, as well as that of the pro-apoptotic Bcl-2-associated X protein 
(Bax), in A2058 cells after incubation with 7 (Figure 14B). As clearly 
shown in the densitometric analysis (Figure 14C), the incubation with the 
inhibitor caused a clear reduction of the bcl-2 level after 8-h treatment, 
and this decrease was still evident after 16 h; on the other hand, a clear 
increase of Bax was observed after 16-h incubation with 7. The 
densitometric analysis also shows the value of the Bcl-2/Bax ratio, 
because its significant reduction observed after 8 and 16 h represents a 
better tool to reveal the regulation of the apoptotic process by 7 (Figure 
14C). Therefore, the increase of ROS, the reduction of mitochondrial 
membrane potential, and the modulation of the protein levels of members 
of the Bcl-2 family suggest the occurrence of a mitochondrial-mediated 
apoptosis induced by compound 7. This hypothesis was further supported 
by the increase of caspase-9 activity measured in A2058 cells after 24-h 
incubation with 7 (Figure 14D). 
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Figure 14: Effect of compound 7 on some apoptotic mitochondrial markers in 
A2058 cells. A. Measurement of the mitochondrial membrane depolarization. Cells were 
treated for the indicated times with 0.5% DMSO (open bars) or 100 µM compound 7 
(black bars). B. Evaluation of Bcl-2 and Bax protein levels. Total protein extracts from 
A2058 cells, incubated with 0.5% DMSO or 100 µM compound 7 for 8 or 16 h, were 
analyzed by Western blotting. β-actin was used as loading control. C. Densitometric 
analysis of the Bcl-2 and Bax protein levels, as well as of the Bcl-2/Bax ratio. D. 
Determination of the caspase-9 enzymatic activity. Total protein extracts from A2058 
cells, incubated with 0.5% DMSO (open bars) or 100 µM compound 7 (black bars) for 
24 h, were assayed for caspase-9 activity. Data from triplicate experiments were reported 
as the means ± SE. *p < 0.05, **p < 0.01, ****p < 0.0001, compared to control cells. 
Other details as described in the Materials and Methods.  
 
The effect of compound 7 was evaluated also in SAN cells and almost 
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overlapping results were obtained (Figure 15). All these finding  suggest 
that the increase of ROS levels associated to an alteration of typical 
mitochondrial markers could contribute or mediate the cytotoxic effect 
exerted by 7 in melanoma cells. 
 
 
Figure 15: Effect of compound 7 on some apoptotic mitochondrial markers in SAN 
cells. (A) Evaluation of Bcl-2 and Bax protein levels. Total protein extracts from SAN 
cells, incubated with 0.5 % DMSO or 100 µM compound 7 for 8 or 16 h, were analyzed 
by Western blotting. GAPDH was used as loading control. (B) Densitometric analysis of 
the Bcl-2 and Bax protein levels, as well as of the Bcl-2/Bax ratio. (C) Determination of 
the caspase-9 enzymatic activity. Total protein extracts from SAN cells, incubated with 
0.5 % DMSO (open bars) or 100 µM compound 7 (black bars) for 24 h, were assayed for 
caspase-9 activity. Data from triplicate experiments were reported as the means ± SE. * 
p < 0.05, ** p < 0.01, **** p < 0.0001, compared to control cells. Other details as 
described in the Materials and Methods. 
 
3.6 Effect of compound 7 on Akt activation and p53 protein levels 
It is known that one of the key proteins involved in the control and 
regulation of cell survival is the kinase B, Akt, in its phosphorylated form 
(pAkt) [34,35]. The molecular mechanisms that regulate the cytotoxic 
potential of cpd 7 were further investigated  through the evaluation of the 
activation state of Akt. Therefore, the protein levels of pAkt have been 
analysed after 2- and 4-h incubation of A2058 cells with 7. As shown in 
Figure 16A, the inhibitor caused an early decrease of the pAkt protein 
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level with respect to total Akt; indeed, this reduction was already evident 
after 2-h and remained detectable until 4-h incubation. An early decrease 
of Akt activation was observed also in SAN cells (not shown). 
It is known that Akt regulates the process of cell survival by 
phosphorylating different substrates, directly or indirectly involved in the 
apoptotic program [36]. One of these targets is p53, a protein with a 
tumor-suppressor activity that regulates the cell cycle, as well as the 
expression of several genes involved in the apoptosis. In detail, Akt 
negatively regulates the apoptosis, by enhancing the degradation of p53 
via its phosphorylation, as well as by promoting the nuclear localization 
and binding of this factor to human murine double-minute 2 (MDM2) 
protein, a negative regulator of p53 [36]. Hence, we tested if the treatment 
of melanoma cells with the CDC25 inhibitor 7 could affect the protein 
levels of p53. As shown in Figure 16B, the increase of p53 level, already 
evident after 8-h incubation, became significant after 16-h incubation. 
Also in SAN cells a time-dependent decrease of the basal level of p53 
was observed (not shown). Therefore,  it could be envisaged that the early 
reduction of pAkt represents an upstream event that triggers other 
molecular events, such as the increase of p53, thus contributing to the 
cytotoxic effect exerted by 7 in melanoma cells. 
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Figure 16: Effect of compound 7 on pAkt and p53 protein levels. A. Evaluation of 
pAkt protein levels. Total protein extracts from A2058 cells, incubated with 0.5% 
DMSO or 100 µM compound 7 for 2 or 4 h, were analyzed by Western blotting using an 
antibody raised against pAkt (Ser473). Akt was used as loading control. Densitometric 
analysis shown in the lower panel. B. Evaluation of p53 protein levels. Total protein 
extracts from A2058 cells, incubated with 0.5% DMSO or 100 µM compound 7 for 8 or 
16 h, were analyzed by Western blotting. GAPDH was used as loading control. 
Densitometric analysis shown in the lower panel. Data from triplicate experiments were 
reported as the means ± SE. *p < 0.05, ***p < 0.001, compared to control cells. Other 
details as described in the Materials and Methods. 
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4. DISCUSSION AND CONCLUSIONS 
The aim of this thesis was the discovery of new inhibitors of CDC25 
phosphatases, because of the potential oncogenic nature of these enzymes 
[8,13]. In particular, the usage of these new molecules in a possible 
therepeutic strategy against melanomaa was considered, because it is 
known that this tumor is highly metastatic and very refractory to any 
conventional therapy [37,38]. A previous investigaton from this 
laboratory led to the characterization of a novel and potent inhibitor of 
CDC25, NSC 119915, possessing a quinonoid structure [24]. This 
compound acted as an irreversible inhibitor of CDC25 and was endowed 
with a cytotoxic activity towards various cancer cell lines. In order to 
ameliorate the inhibitory power of this compound, different 
chemoinformatic approaches were combined [39,40] and led to the design 
of 126 potential inhibitors of CDC25 proteins. Among them, 25 top-
ranked close analogs of our lead compound NSC 119915 were chosen 
and synthesized, because they were expected to possess inhibitory activity 
against the CDC25A, -B and -C phosphatases. Interestingly, among the 
25 candidates, eight compounds, sharing the same 6-xanthone motif (5-9, 
21, 24, and 25), caused an in vitro dose-dependent inhibition of the 
CDC25B phosphatase activity. Kinetic analyses revealed that these 
compounds inhibited the three different CDC25 proteins in a 
noncompetitive manner with Ki values comparable to those of the lead 
compound NSC 119915. Only slight differences were found in the 
inhibition power towards the three CDC25 forms, CDC25A being slightly 
higher sensitive towards the inhibitors, and CDC25C having a moderately 
lower responsiveness. 
When melanoma is diagnosed at a late stage, it becomes one of the more 
aggressive tumours, frequently linked to a poor prognosis. As CDC25 
phosphatases, in combination with other cell cycle regulators, are 
involved in melanoma growth and progression [25,41], we have decided 
to evaluate the effects of NSC 119915 and its close analogs, i.e. the eight 
potent inhibitors 5-9, 21, 24, and 25 and the weak inhibitor 3, on the 
growth rate of two melanoma cell lines, A2058 and SAN. The results of 
this investigation showed that only one analog, cpd 7, was capable to 
reduce the cell growth rate of both A2058 and SAN melanoma cells. 
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However, in SAN cells, also the analogs 6 and 24, as well as in some 
experimental conditions also NSC 119915, caused a significant decrease 
of the cell growth rate. The failure of compounds 5, 8, 9, 21 and 25 to 
inhibit cell proliferation, despite their in vitro potent inhibition of all three 
CDC25 phosphatases, could be due to poor permeability into cells, 
chemical instability, unfavourable compartmentalization, active 
metabolism into inactive compounds, presence of unidentified binding 
proteins, or a combination of these factors. In conclusion, for its common 
behavior in both melanoma cell lines, 7 was selected as the most 
promising compound for further investigation of its antimelanoma effects. 
CDC25s are fine regulators of the different phases of cell cycle. Hence, 
we checked if the reduction of cell growth rate caused by 7 was 
associated to an alteration of cell cycle progression. A significant 
reduction of the G0/G1 phase and an increase of the G2/M phase occurred 
in both melanoma cells lines after 16-h treatment and continued up to 24-
h. It is known that many cytotoxic compounds, as well as various anti-
cancer drugs, cause DNA damage [42,43]. This event activates different 
checkpoint pathways, which can induce an arrest of cell proliferation, 
thus enabling cells to DNA repair in order to prevent cell death. On the 
other hand, if the mechanisms involved in the DNA repair are ineffective 
and the DNA damage is not completely repaired, cells can be committed 
to programmed cell death. As CDC25 proteins exert a pivotal role in the 
regulation of cell division cycle [8], their overexpression might facilitate 
checkpoint exit and contribute to neoplastic transformation. Hence, 
CDC25 inhibition, inactivation or degradation can amplify the cytotoxic 
activity of some compounds. The treatment of melanoma cells with cpd 7 
caused a modulation of the CDC25 protein levels. In particular, we 
observed an early reduction of CDC25A associated to a progressive and 
strong decrease of CDC25C. These results suggest that the observed 
G2/M arrest of cell cycle in melanoma cells could depend on an inhibition 
of phosphatase activity of CDC25 proteins, as well as on a reduction of 
the protein levels of CDC25A and, more consistently, of CDC25C. This 
behavior seems in good agreement with the major role played by 
CDC25C in the control of the G2/M progression of cell cycle [44]. 
The reduction of cell growth rate and the G2/M block of cell cycle could 
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evoke the beginning of a cell death program. Indeed, cpd 7 activated a 
time-dipendent apoptotic program in melanoma cells, as revealed by PI 
incorporation experiments and measurements of caspase-3 activity. 
Hence, we can infer that the apoptosis observed in melanoma cells 
represents a consecutive process to the long cell cycle blockage in the 
G2/M phase. 
It is known that quinonoid structures, as those of the most active CDC25 
inhibitors, are good substrates for the beginning of a redox cycle, and that 
an increased ROS level may cause severe damages to the CDC25 
structure [20,45,46]. Indeed, quinonoid compounds exert their inhibitory 
activity on CDC25 through the oxidation of cysteine residues located in 
the active site [21,24]. On the other hand, the increase of ROS level may 
be deleterious also to other cellular components, thus activating various 
metabolic pathways that control the cell cycle. Compound 7 induced an 
increase of the intracellular ROS levels in both melanoma cells, an event 
reverted by NAC, whereas apocynin was ineffective. It is known that 
NAC is the precursor of glutathione, the main intracellular antioxidant, 
and that the target of apocynin is NADPH oxidase, the most important 
ROS source located on the membrane. The different effect exerted by 
these two antioxidant molecules led to the speculation that lipophilicity of 
7 could allow its efficient crossing through the cellular membrane; 
however, the precence of some polar groups in 7 probably prevents its 
stable interaction with the inter-membrane components, such as NADPH 
oxidase. However, the reversion of apoptosis in the presence of NAC 
suggests that the increase of intracellular ROS levels may be considered 
as an early event involved in the signalling triggered by cpd 7. 
The apoptotic machinery is an essential element of cell cycle checkpoints 
and the cytotoxic effects of many drugs are mediated by mitochondrion 
through the activation of an intrinsic apoptotic pathway. Bcl-2 family 
members play a role not only in the regulation of apoptosis but also in the 
control of cell cycle [47]. In this work, the observed increase of ROS 
levels, as well as the decrease of the crucial parameter for controlling life 
and death of a cell, i.e. the Bcl-2/Bax ratio, are markers of an involvement 
of the mitochondrion in the apoptotic program triggered by 7 in our cell 
system. This hypothesis was further supported by the reduction of 
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mitochondrial membrane potential, as well as by the increase of caspase-9 
activity. Hence, our findings indicate that the alteration of the intracellular 
redox state induced by 7 could represent an underlying mechanism for the 
activation of the mitochondrial apoptotic pathway in melanoma cells. 
Chemoresistance is a typical hallmark of advanced melanomas. It has 
been reported that the aggressive nature of melanoma is related to an 
accumulation of mutations in several key proliferation-regulating 
mechanisms, as well as in apoptosis-controlling pathways [48]. Defects in 
Akt expression occur in a significant proportion of malignant melanomas 
[49]. Under this concern, the early reduction of the pAkt protein levels 
caused by 7 was very interesting, because it has been demonstrated that 
CDC25B mediates the activation of Akt, probably through a 
dephosphorylation mechanism of specific protein kinases [50,51]. A key 
molecule involved in the regulation of cell cycle and apoptosis pathway is 
p53. Frequently, in melanoma this protein is not mutated, but its impaired 
functions depend on high levels of the phosporylated form of MDM2, a 
typical inhibitor of p53 [52]. The time-dipendent decrease of the basal 
level of p53 observed in both melanoma cell, and its higher level 
measured in treated cells mainly after a late incubation with 7, suggest 
that this compound could affect the p53 protein stability. Indeed, higher 
levels of p53 in treated compared to untreated cells could be ascribable to 
a reduced activation of Akt, because this protein is responsible for the 
MDM2 phosphorylation [53,54]. On the other hand, it is likely that the 
reduced activation of Akt modulates the functions of other downstream 
proteins; under this concern, one possible candidate seems to be Bax, 
because of the increased levels of this pro-apoptotic factor observed upon 
treatment of A2058 with 7. In conclusion, we suggest that the early 
reduction of pAkt levels could be related to a concomitant impairment of 
CDC25 functions. In turn, the reduced activation of Akt could cause the 
deregulation of other downstream pathways, leading to an increase of 
ROS level and later of p53 levels. 
Hence, our data indicate that the anti-proliferative and pro-apoptotic 
effects triggered on melanoma cells after treatment with compound 7 is 
probably related to the inhibition potency exhibited by this molecule on 
the CDC25 phosphatase activity, as well as to the modulation of its 
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protein levels among the different forms. Therefore, the deregulation of 
CDC25 in melanoma cells suggests that this crucial element of cell cycle 
could be considered as a possible oncotarget in vivo. Under this concern, 
it is known that advanced anti-melanoma strategies are based on the usage 
of BRAF inhibitors, that selectively block the proliferation of melanoma 
cells harboring the BRAFV600E mutation [48]. However, the success of 
this therapy is not definitive, because usually the patients relapse because 
of acquired drug resistance, possibly due to the activation of others 
survival pathways. It has been observed that in many cases the anti-cancer 
therapies can induce the establishment of a pro-survival niche, allowing 
for therapeutic escape. In particular, melanoma cells readily adapt to 
nearly every pharmacological intervention and possess multiple routes to 
treatment escape. Loss of PTEN, a negative Akt regulator, as well as the 
increased Akt signalling, mediate a mesenchymal switch. In 
BRAFV600E/PTEN-null melanoma cell lines, verumafenib is able to 
induce epithelial-to-mesenchymal transition (EMT). EMT is characterized 
by increased motility, upregulated expression of extracellular matrix 
factors, such as fibronectin (FN), and resistance to drug and apoptosis. 
Attachment to extracellular matrix has been identified as an important 
mechanism of drug resistance in a number of tumour systems. In 
melanoma cells, adhesion to FN prevents the induction of anoikis through 
increased PI3K signalling. The role of PI3K/Akt signalling in the adaptive 
responses that drive therapeutic escape was suggested by the finding that 
BRAF/PI3K inhibitor combination led to increased cytotoxicity [55]. 
An alternative strategy to reduce the therapeutic escape could be 
represented by the combination of two different drugs, cotargeting 
independent survival pathways that are critical for development and 
maintenance of melanoma. Hence, the study of the effects of CDC25 
inhibitors in melanoma cells could be helpful for finding other molecular 
pathways, as possible targets for melanoma treatment. Future research 
will be devoted to the amelioration of the therapeutical potential of 
compound 7; in particular, structural refinements will be performed to 
increase its inhibition power on CDC25, as well as the cytotoxic effects. 
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